In fact, participants falling in the lowest quartile had worse glycemic control and higher prevalence of insulin treatment, obesity, atherogenic dyslipidemia, and smoking habits, but lower total and LDL cholesterol, systolic BP and prevalence of other treatments than those falling in the highest quartile. The gene discussed is INS; the disease is metabolic syndrome.